Advertisement

International Journal of Colorectal Disease

, Volume 22, Issue 11, pp 1331–1338 | Cite as

Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients

  • Eva Angenete
  • Marcus Langenskiöld
  • Ingrid Palmgren
  • Peter Falk
  • Tom Öresland
  • Marie-Louise Ivarsson
Original Article

Abstract

Background

Rectal cancer patients are treated with surgery and sometimes radiotherapy. Transforming growth factor-β1 (TGF-β1) acts both as an inhibitor of tumour growth and as a promoter of tumour progression. The aim of this study was to determine the levels of TGF-β1 in tumour tissue, adjacent mucosa and plasma in rectal cancer patients and relate these to the effect of radiotherapy and clinical outcome.

Materials and methods

One hundred and ten patients scheduled for rectal cancer surgery were included, 49% received pre-operative radiotherapy three-field treatment 5 × 5 Gy. Blood samples and biopsies were taken during surgery and later assayed with enzyme-linked immunosorbent assay for total TGF-β1 and active TGF-β1. Patients were then followed for 3 years.

Results

Total and active TGF-β1 was higher in tumour tissue compared with rectal mucosa (p < 0.0001). Active TGF-β1 in tumour tissue and rectal mucosa was lower in the irradiated group (p = 0.007; p < 0.0001). Total TGF-β1 was higher in patients with metastases at primary diagnosis (p = 0.005) compared to patients without. In patients who later developed metastases, the levels of active TGF-β1 in plasma were lower (p = 0.004). Local recurrence was associated with lower levels of total TGF-β1 in the rectal mucosa (p = 0.038).

Conclusions

Higher levels of total TGF-β1 in tumour tissue at surgery may be indicative of distant metastases, and low levels of active TGF-β1 in plasma may indicate a risk of developing secondary metastases. Lower levels of total TGF-β1 in rectal mucosa may influence risk of local recurrence. Measurement of TGF-β1 in rectal cancer patients may be of clinical use in the future.

Keywords

Rectal cancer Irradiation TGF-beta Extracellular matrix Distant metastases 

Notes

Acknowledgements

The authors would like to thank Mats Gunnarsson for statistical advice and Kristina Ticehurst for valuable comments and discussions.

Funding

Halland’s Research Council, Gothenburg Medical Society, Swedish Research Council, JK-fonden, Gothenburg, Assar Gabrielsson foundation.

References

  1. 1.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646CrossRefPubMedGoogle Scholar
  2. 2.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (1997) Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRefGoogle Scholar
  3. 3.
    Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U (2005) Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23:5644–5650CrossRefPubMedGoogle Scholar
  4. 4.
    Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131CrossRefPubMedGoogle Scholar
  5. 5.
    Cedermark B, Johansson H, Rutqvist LE, Wilking N (1995) The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 75:2269–2275CrossRefPubMedGoogle Scholar
  6. 6.
    Cedermark B, Theve NO, Rieger A, Wahren B, Glas JE, Rubio C, Ost A, Brostrom L, Ekelund G, Forsgren L et al (1985) Preoperative short-term radiotherapy in rectal carcinoma. A preliminary report of a prospective randomized study. Cancer 55:1182–1185CrossRefPubMedGoogle Scholar
  7. 7.
    Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol 23:8697–8705CrossRefPubMedGoogle Scholar
  8. 8.
    Lawrence DA (2001) Latent-TGF-beta: an overview. Mol Cell Biochem 219:163–170CrossRefPubMedGoogle Scholar
  9. 9.
    Hill RP, Rodemann HP, Hendry JH, Roberts SA, Anscher MS (2001) Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 49:353–365CrossRefPubMedGoogle Scholar
  10. 10.
    Wang J, Zheng H, Sung CC, Richter KK, Hauer-Jensen M (1998) Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy. Am J Pathol 153:1531–1540CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Denham JW, Hauer-Jensen M (2002) The radiotherapeutic injury—a complex ‘wound’. Radiother Oncol 63:129–145CrossRefPubMedGoogle Scholar
  12. 12.
    Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, Brattain MG (1992) TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116:187–196CrossRefPubMedGoogle Scholar
  13. 13.
    Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A (1995) High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4:549–554PubMedGoogle Scholar
  14. 14.
    Narai S, Watanabe M, Hasegawa H, Nishibori H, Endo T, Kubota T, Kitajima M (2002) Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer. Int J Cancer 97:508–511CrossRefPubMedGoogle Scholar
  15. 15.
    Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y, Kawata S (2001) Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7:1258–1262PubMedGoogle Scholar
  16. 16.
    Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, Tepetes K, Kalogeropoulou C, Tsota I, Kourelis T, Makatsoris T, Karavias D, Scopa CD, Bonikos DS, Kalofonos HP, Petsas T (2004) The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 180:201–208CrossRefPubMedGoogle Scholar
  17. 17.
    Ivarsson ML, Bergstrom M, Eriksson E, Risberg B, Holmdahl L (1998) Tissue markers as predictors of postoperative adhesions. Br J Surg 85:1549–1554CrossRefPubMedGoogle Scholar
  18. 18.
    Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y (1996) High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110:375–382CrossRefPubMedGoogle Scholar
  19. 19.
    Richter KK, Fink LM, Hughes BM, Shmaysani HM, Sung CC, Hauer-Jensen M (1998) Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum. Am J Surg 176:642–647CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson LB, Adawi D, Agren MS, Jorgensen LN, Wittgren L, Mattsson S, Blomquist P, Gottrup F, Jeppsson B (2006) Combination of pre-operative radiotherapy and surgery suppresses local accumulation of collagen and TGF-beta1 in rats. J Surg Res 133:136–142CrossRefPubMedGoogle Scholar
  21. 21.
    Barcellos-Hoff MH (1993) Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 53:3880–3886PubMedGoogle Scholar
  22. 22.
    Angenete E, Langenskiold M, Falk P, Ivarsson ML (2007) Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int J Colorectal Dis (in press)Google Scholar
  23. 23.
    Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176PubMedPubMedCentralGoogle Scholar
  24. 24.
    Dahlberg M, Glimelius B, Graf W, Pahlman L (1998) Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 41:543–549 discussion 549–551CrossRefPubMedGoogle Scholar
  25. 25.
    Holm T, Singnomklao T, Rutqvist LE, Cedermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 78:968–976CrossRefPubMedGoogle Scholar
  26. 26.
    Kushiyama Y, Fukuda R, Suetsugu H, Kazumori H, Ishihara S, Adachi K, Kinoshita Y (2000) Site-dependent production of transforming growth factor beta1 in colonic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 136:201–208CrossRefPubMedGoogle Scholar
  27. 27.
    Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 85:554–561CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Eva Angenete
    • 1
  • Marcus Langenskiöld
    • 2
  • Ingrid Palmgren
    • 1
  • Peter Falk
    • 1
  • Tom Öresland
    • 1
  • Marie-Louise Ivarsson
    • 3
  1. 1.Department of Surgery, Sahlgrenska University Hospital/ÖstraGöteborg UniversityGothenburgSweden
  2. 2.Department of Vascular SurgerySahlgrenska University Hospital/Sahlgrenska, Göteborg UniversityGothenburgSweden
  3. 3.Department of SurgeryKungsbacka Hospital, Göteborg UniversityKungsbackaSweden

Personalised recommendations